GlassScriptPhysician profile
Kevin B Zent
NPI 1255380648
$2,757.83
in general payments reported to CMS, 2019-2025
27 companies · $772 in 2025
The $772 reported for 2025 was more than what 81% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $55.31 · 2020: $16.28 · 2021: $254 · 2022: $347 · 2023: $671 · 2024: $642 · 2025: $772.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,086.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,085.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,274.56 | 2021-2025 | Vraylar, Mavyret |
| Gilead Sciences, INC. | $325.54 | 2022-2025 | |
| Axsome Therapeutics, INC. | $158.61 | 2024-2025 | Auvelity |
| Baxter Healthcare | $120.59 | 2023-2025 | Hillrom - Carnation Ambulatory Monitor |
| Pfizer INC. | $90.77 | 2019-2025 | |
| Braeburn INC. | $88.00 | 2023-2024 | Brixadi |
| Lilly USA, LLC | $83.42 | 2021-2025 | Mounjaro, Zepbound |
| Takeda Pharmaceuticals U.S.A., INC. | $66.68 | 2021-2022 | |
| Novo Nordisk INC | $56.50 | 2019-2025 | Ozempic, Rybelsus |
| Ironshore Pharmaceuticals INC. | $56.23 | 2023-2024 | Jornay Pm |
| Boehringer Ingelheim Pharmaceuticals, INC. | $47.04 | 2021-2025 | Jardiance |
| Alkermes, INC. | $43.27 | 2023 | Vivitrol |
| Vanda Pharmaceuticals INC. | $38.80 | 2024 | Fanapt |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $36.18 | 2019-2021 | |
| Glaxosmithkline, LLC. | $32.02 | 2020-2025 | Shingrix, Bexsero, Arexvy |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $27.77 | 2023 | Injectafer |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $25.38 | 2022-2023 | |
| Vbi Vaccine (Delaware) INC. | $23.66 | 2022 | |
| Hologic Sales and Service, LLC | $23.39 | 2025 | Aptima, Thinprep 2000 Processor |
| Janssen Pharmaceuticals, INC | $20.98 | 2022 | |
| Indivior INC. | $20.89 | 2025 | Sublocade |
| Merck Sharp & Dohme LLC | $20.70 | 2025 | Capvaxive, Enflonsia, Gardasil 9 |
| Astrazeneca Pharmaceuticals LP | $16.76 | 2025 | Airsupra |
| Otsuka America Pharmaceutical, INC. | $16.12 | 2025 | Rexulti |
| Exact Sciences Corporation | $15.80 | 2025 | The Cologuard Plus Collection Kit |
| Teva Pharmaceuticals USA, INC. | $14.28 | 2024 | |
| Shire North American Group INC | $13.89 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kevin Zent listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.